| Jill M Hardy, LPN | |
|
2215 Fuller Rd, Ann Arbor, MI 48105-2303 | |
| (734) 769-5500 | |
| Not Available |
| Full Name | Jill M Hardy |
|---|---|
| Gender | Female |
| Speciality | Licensed Practical Nurse |
| Location | 2215 Fuller Rd, Ann Arbor, Michigan |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1851090047 | NPI | - | NPPES |
| 999999999 | Other | 99999999 |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164W00000X | Licensed Practical Nurse | 4703125446 (Michigan) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Jill M Hardy, LPN 2215 Fuller Court, Ann Arbor, MI 48105 Ph: (734) 769-5500 | Jill M Hardy, LPN 2215 Fuller Rd, Ann Arbor, MI 48105-2303 Ph: (734) 769-5500 |
News Archive
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of diabetic neuropathy, a drug that has disease-modifying potential would earn 40 percent patient share in the U.S., according to surveyed U.S. neurologists. Similarly, in Europe, such a drug would earn a comparable patient share of 43 percent, according to surveyed European neurologists.
A small filter the size of a contact lens could possibly make life easier for some of the estimated 500 million people worldwide who suffer from itching, sneezing and a runny nose as soon as the pollen season starts.
In a paper recently uploaded to the preprint server medRxiv by Edward Málaga Trillo et al. (April 29th, 2021), these methods are tested in combination with CRISPR-Cas detection in the field, demonstrating a sensitivity and specificity of 93.8% and 99%, respectively.
In September 2009, the Kansas City District Office of the Food and Drug Administration (FDA) submitted a recommendation of approval to the Center for Drug Evaluation and Research for The University of Iowa Pharmaceuticals (UIP) to manufacture and test an aseptically filled, sterile prescription drug product for a commercial client. The drug product contains a new chemical entity and is a sterile solution that is aseptically filled into vials.
The U.S. Food and Drug Administration today approved Fycompa (perampanel) tablets to treat partial onset seizures in patients with epilepsy ages 12 years and older.
› Verified 8 days ago
Michael Atiefu, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 2667 Adrienne Dr, Ann Arbor, MI 48103 Phone: 734-383-2799 | |
Lisa Heard, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 2215 Fuller Road, Ann Arbor, MI 48105 Phone: 419-259-2000 | |
Linmyers Jean Myers, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 2850 S Industrial Hwy Ste 75, Ann Arbor, MI 48104 Phone: 734-677-1515 | |
Stephanie Biccum, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 2215 Fuller Rd, Ann Arbor, MI 48105 Phone: 517-764-3609 | |
Jacqueline Maxey, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 2850 S Indurstrial Hwy, Suite 75, Ann Arbor, MI 48104 Phone: 734-477-7204 | |
Crystal Crawford, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 2557 Hawks Rd, Ann Arbor, MI 48108 Phone: 734-945-3054 | |
Katrina Louise Person, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 2215 Fuller Rd, Ann Arbor, MI 48105 Phone: 734-222-4212 Fax: 734-845-5301 |